Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma

摘要: Abstract Introduction Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subset of non–small cell lung cancer with limited treatment options. The molecular characterization PSC has been strongly hampered by the relative rarity these tumors. However, understanding genetic bases PSCs critical to pave way new In this work, we aimed explore complexity asset investigate its prognostic impact on survival in large cohort patients PSC. Methods Next-generation sequencing analysis panel 26 genes potential clinical relevance was performed surgical specimens 49 PSCs. profiles patient association between the alterations clinicopathological features were tested. Results Fifty-five somatic mutations detected 13 genes. Thirty-nine (80%) showed at least one mutation. Survival probability decreased mutated compared those without ( p  = 0.02). particular, Kirsten rat sarcoma viral oncogene homolog gene KRAS ), alone or combination tumor protein p53 TP53 ) mutations, associated occurrence local metastases recurrence. Finally, comparison our results data Cancer Genome Atlas that have mutational profile similar smokers' adenocarcinoma. Conclusions Overall, provides further information demonstrates for first time role driving aggressiveness type cancer.